These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9083471)

  • 1. GRID/GOLPE 3D quantitative structure-activity relationship study on a set of benzamides and naphthamides, with affinity for the dopamine D3 receptor subtype.
    Nilsson J; Wikström H; Smilde A; Glase S; Pugsley T; Cruciani G; Pastor M; Clementi S
    J Med Chem; 1997 Mar; 40(6):833-40. PubMed ID: 9083471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
    Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
    J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New series of morpholine and 1,4-oxazepane derivatives as dopamine D4 receptor ligands: synthesis and 3D-QSAR model.
    Audouze K; Nielsen EØ; Peters D
    J Med Chem; 2004 Jun; 47(12):3089-104. PubMed ID: 15163190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPECT tracer [(123)I]IBZM has similar affinity to dopamine D2 and D3 receptors.
    Videbaek C; Toska K; Scheideler MA; Paulson OB; Moos Knudsen G
    Synapse; 2000 Dec; 38(3):338-42. PubMed ID: 11020237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-selectivity investigations of D2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D3 selective PET radioligands.
    Salama I; Hocke C; Utz W; Prante O; Boeckler F; Hübner H; Kuwert T; Gmeiner P
    J Med Chem; 2007 Feb; 50(3):489-500. PubMed ID: 17266201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and structure-activity relationships of naphthamides as dopamine D3 receptor ligands.
    Huang Y; Luedtke RR; Freeman RA; Wu L; Mach RH
    J Med Chem; 2001 May; 44(11):1815-26. PubMed ID: 11356115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multiway 3D QSAR analysis of a series of (S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-methoxybenzamides.
    Nilsson J; Homan EJ; Smilde AK; Grol CJ; Wikström H
    J Comput Aided Mol Des; 1998 Jan; 12(1):81-93. PubMed ID: 9570091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
    Audinot V; Newman-Tancredi A; Gobert A; Rivet JM; Brocco M; Lejeune F; Gluck L; Desposte I; Bervoets K; Dekeyne A; Millan MJ
    J Pharmacol Exp Ther; 1998 Oct; 287(1):187-97. PubMed ID: 9765337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zinc modulates antagonist interactions with D2-like dopamine receptors through distinct molecular mechanisms.
    Schetz JA; Chu A; Sibley DR
    J Pharmacol Exp Ther; 1999 May; 289(2):956-64. PubMed ID: 10215675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands.
    Ji M; Chen J; Ding K; Wu X; Varady J; Levant B; Wang S
    Bioorg Med Chem Lett; 2005 Mar; 15(6):1701-5. PubMed ID: 15745825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonist-radioligand binding to D2L-receptors in intact cells.
    Packeu A; De Backer JP; Van Liefde I; Vanderheyden PM; Vauquelin G
    Biochem Pharmacol; 2008 Jun; 75(11):2192-203. PubMed ID: 18436192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substituted [(4-phenylpiperazinyl)-methyl]benzamides: selective dopamine D4 agonists.
    Glase SA; Akunne HC; Georgic LM; Heffner TG; MacKenzie RG; Manley PJ; Pugsley TA; Wise LD
    J Med Chem; 1997 Jun; 40(12):1771-2. PubMed ID: 9191952
    [No Abstract]   [Full Text] [Related]  

  • 15. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
    Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
    J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QSAR modeling on dopamine D2 receptor binding affinity of 6-methoxy benzamides.
    Samanta S; Debnath B; Gayen S; Ghosh B; Basu A; Srikanth K; Jha T
    Farmaco; 2005 Oct; 60(10):818-25. PubMed ID: 16055122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A quantitative structure-activity relationship for some dopamine D2 antagonists of benzamide type.
    Norinder U; Högberg T
    Acta Pharm Nord; 1992; 4(2):73-8. PubMed ID: 1388772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (Aryloxy)alkylamines as selective human dopamine D4 receptor antagonists: potential antipsychotic agents.
    Unangst PC; Capiris T; Connor DT; Doubleday R; Heffner TG; MacKenzie RG; Miller SR; Pugsley TA; Wise LD
    J Med Chem; 1997 Dec; 40(25):4026-9. PubMed ID: 9406594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dibenzazecine compounds with a novel dopamine/5HT2A receptor profile and 3D-QSAR analysis.
    Hamacher A; Weigt M; Wiese M; Hoefgen B; Lehmann J; Kassack MU
    BMC Pharmacol; 2006 Sep; 6():11. PubMed ID: 16978403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.